A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 23 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HMPL-760 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
Focus Adverse reactions; First in man
Sponsors HUTCHMED

Most Recent Events

12 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment.
17 Jun 2022 Trial design presented at the 27th Congress of the European Haematology Association
08 Feb 2022 Planned initiation date changed from 30 Dec 2021 to 15 Feb 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight